Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer

BJU International

Volumn 112, Issue 4, 2013, Pages

  Won, Andy C M ^a   Gurney, Howard ^b   Marx, Gavin ^c   De Souza, Paul ^d   Patel, Manish I ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d LIVERPOOL HOSPITAL   (Australia)

Author keywords

castrate resistant; external beam radiotherapy; morbidity; prostate cancer; prostatectomy

Indexed keywords

TESTOSTERONE;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; AUSTRALIA; BLADDER NECK STENOSIS; BONE METASTASIS; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; HEMATURIA; HUMAN; HYDRONEPHROSIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PELVIS PAIN SYNDROME; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATITIS; RADICAL RETROPUBIC PROSTATECTOMY; URETER OBSTRUCTION; URINE RETENTION; VISCERAL METASTASIS;

CASTRATE-RESISTANT; EXTERNAL BEAM RADIOTHERAPY; MORBIDITY; PROSTATE CANCER; PROSTATECTOMY;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PALLIATIVE CARE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 84880775914     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12169     Document Type: Article

References (14)

1. Chan JM, Jou RM, Carroll PR,. The relative impact and future burden of prostate cancer in the United States. J Urol 2004; 172: 13-16
2. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011; 364: 1708-1717
3. Zelefsky MJ, Reuter VE, Fuks Z, et al. Influence of local tumour control on distal metastases after external beam radiotherapy for prostate cancer. J Urol 2008; 179: 1368-1373
4. Thompson IM, Tangen C, Basler J, Crawford ED,. Impact of previous local treatment for prostate cancer on subsequent metastatic disease. J Urol 2002; 168: 1008-1012
5. Lilleby W, Fossa S, Wahre H, Olsen D,. Long-term morbidity and quality of life in patients with localised prostate cancer undergoing definitive radiotherapy or radical prostatectomy. Int J Radiat Oncol Biol Phys 1999; 43: 735-743
6. Halabi S, Vogelzang NJ, Ou S-S, Small EJ,. The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: a pooled analysis of 9 cancer and leukemia group B trials. J Urol 2007; 177: 531-534
7. Cheng CWS, Bergstralh EJ, Zincke H,. Stage D1 prostate cancer: a nonrandomized comparison of conservative treatment options versus radical prostatectomy. Cancer Suppl 1993; 71: 996-1004
8. Schmeller N, Lubos W,. Early endocrine therapy verus radical prostatectomy combined with early endocrine therapy for stage D1 prostate cancer. Br J Urol 1997; 79: 226-234
9. Gjertson C, Asher K, Sclar J, et al. Local control and long-term disease-free survival for stage D1 (T2-T4N1-N2M0) prostate cancer after radical prostatectomy in the PSA era. Urology 2007; 70: 723-727
10. Grimm M-O, Kamphausen H, Hugenschmidt H, Stephen-Odenthal M, Ackermann R, Vogeli TA,. Clinical outcome of patients with lymph node positive prostate cancer after radical prostatectomy versus androgen deprivation. Eur Urol 2012; 41: 628-634
11. Steinberg GD, Epstein JI, Piantadosi S, Walsh PC,. Management of stage D1 adenocarcinoma of the prostate: the Johns Hopkins experience 1974 to 1987. J Urol 1990; 144: 1425-1432
12. Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherpy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009; 373: 301-308
13. Warde P, Ding K, Kirkbride P, et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 2011; 17: 2104-2111
14. Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26: 242-245